Has the Hong Kong Healthcare Distributors Industry valuation changed over the past few years?

Investors are pessimistic on the Hong Kong Healthcare Distributors industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 7.9x which is lower than its 3-year average PE of 10.0x. The industry is trading close to its 3-year average PS ratio of 0.14x.

How does Hong Kong Healthcare Distributors compare with similar industries?

There is insufficient data on the sub-industries of this industry.

Hong Kong (HSI) Healthcare Distributors Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 09 Aug 2022	HK$68.0b	HK$629.4b	HK$8.6b	15.4x	7.9x	0.1x
Thu, 07 Jul 2022	HK$73.4b	HK$633.2b	HK$8.7b	16.7x	8.5x	0.1x
Sat, 04 Jun 2022	HK$70.9b	HK$638.6b	HK$8.8b	16.1x	8x	0.1x
Mon, 02 May 2022	HK$71.3b	HK$635.0b	HK$8.6b	17.2x	8.3x	0.1x
Wed, 30 Mar 2022	HK$70.6b	HK$657.6b	HK$8.9b	15.5x	8x	0.1x
Fri, 25 Feb 2022	HK$73.4b	HK$647.4b	HK$9.0b	16.6x	8.1x	0.1x
Sun, 23 Jan 2022	HK$71.6b	HK$643.3b	HK$9.0b	16.3x	8x	0.1x
Tue, 21 Dec 2021	HK$63.2b	HK$640.9b	HK$8.9b	13.8x	7.1x	0.1x
Thu, 18 Nov 2021	HK$68.8b	HK$637.9b	HK$8.9b	14.2x	7.7x	0.1x
Sat, 16 Oct 2021	HK$75.6b	HK$622.5b	HK$8.7b	13.5x	8.6x	0.1x
Mon, 13 Sep 2021	HK$75.2b	HK$619.7b	HK$8.8b	16.1x	8.5x	0.1x
Wed, 11 Aug 2021	HK$76.7b	HK$619.7b	HK$8.8b	14.7x	8.7x	0.1x
Sun, 06 Jun 2021	HK$92.7b	HK$584.1b	HK$8.2b	13.4x	11.3x	0.2x
Wed, 10 Mar 2021	HK$65.2b	HK$557.2b	HK$7.7b	10x	8.5x	0.1x
Tue, 01 Dec 2020	HK$67.6b	HK$516.6b	HK$6.6b	12.4x	10.2x	0.1x
Fri, 04 Sep 2020	HK$68.0b	HK$482.3b	HK$5.8b	16.1x	11.8x	0.1x
Mon, 08 Jun 2020	HK$68.5b	HK$486.7b	HK$6.5b	15.4x	10.5x	0.1x
Sun, 01 Mar 2020	HK$84.6b	HK$489.7b	HK$6.7b	11.1x	12.7x	0.2x
Wed, 04 Dec 2019	HK$85.7b	HK$459.1b	HK$6.5b	11.2x	13.2x	0.2x
Sat, 07 Sep 2019	HK$92.8b	HK$448.5b	HK$6.3b	12.2x	14.8x	0.2x


HK Market	0.21%
Healthcare	3.41%
Healthcare Services	1.18%
Healthcare Distributors	1.94%
Managed Healthcare	16.67%
Healthcare Facilities	0.87%
Healthcare Services	0.84%

Company	Last Price	7D	1Y	Valuation
1099 Sinopharm Group	HK$17.78	2.1% +HK$1.1b	-16.7%	PE6x
1931 IVD Medical Holding	HK$2.41	3.0% +HK$94.8m	-12.4%	PE16.1x
673 China Health Group	HK$0.61	17.3% +HK$63.9m	-17.6%	PS2.7x
1110 Kingworld Medicines Group	HK$0.48	2.1% +HK$6.2m	-38.5%	PE8.5x

Jul 14

Charmacy Pharmaceutical Co., Ltd. Announces Executive Changes

Charmacy Pharmaceutical Co., Ltd. appointed Zhang Hanzi (as an executive Director with effect from the date of the EGM until the expiration of the term of the third session of the Board and she is eligible for re-election upon expiry of her term. The Company will enter into a letter of appointment with Ms. Zhang. Ms. Zhang's annual salary as an executive Director is RMB50,000, which is determined with reference to her qualifications, experiences, duties and responsibilities within the Company as well as the prevailing market rate for candidates with comparable qualifications. The profile of Ms. Zhang has been set out in the Circular. As at the date of this announcement, there has been nochange in such information. Save as disclosed in the Circular, as at the date of this announcement, Ms. Zhang has confirmed that (i) she has not held any directorship in any other public company in the past three years whose securities are listed in Hong Kong or any overseas securities market; (ii) she has no relationship with any Director, supervisor, senior management or substantial or controlling shareholder of the Company, nor has she held any position in the Company or any of its subsidiaries; (iii) she has no interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance of Hong Kong (Chapter 571 of the Laws of Hong Kong); and (iv) there is no other information in relation to Ms. Zhang which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules, nor are there other matters in relation to her appointment that need to be brought to the attention of the Shareholders. The Board announced that Ms. Fu Zheng ("Ms. Fu") has been appointed as a non-executive Director with effect from the date of the EGM until the expiration of the term of the third session of the Board and she is eligible for re-election upon expiry of her term. The Company will enter into a letter of appointment with Ms. Fu. Ms. Fu will not receive any remuneration for serving as a non-executive Director. The profile of Ms. Fu has been set out in the Circular. As at the date of this announcement, there has been no change in such information. Save as disclosed in the Circular, as at the date of this announcement, Ms. Fu has confirmed that(i) she has not held any directorship in any other public company in the past three years whose securities are listed in Hong Kong or any overseas securities market; (ii) she has no relationship with any Director, supervisor, seniormanagement or substantial or controlling shareholder of the Company, nor has she held any position in the Company or any of its subsidiaries; (iii) she has no interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance of Hong Kong (Chapter 571 of the Laws of Hong Kong); and (iv) there is no other information in relation to Ms. Fu which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules, nor are there other matters in relation to her appointment that need to be brought to the attention of the Shareholders.

Hong Kong (HSI) Healthcare Distributors Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

673

Full year 2022 earnings released: HK$0.003 loss per share (vs HK$0.002 loss in FY 2021)

9955

High number of new and inexperienced directors

1099

Is Sinopharm Group (HKG:1099) Using Too Much Debt?

3390

Tycoon Group Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

2289

Charmacy Pharmaceutical Co., Ltd. Announces Executive Changes

1110

Co-Founder recently bought HK$297k worth of stock

1345

Investor sentiment improved over the past week

6833

Investor sentiment deteriorated over the past week

1931

Investor sentiment improved over the past week

6108

Insider recently sold HK$199m worth of stock